Jazz Pharmaceuticals plc 8-K

What Happened

• Jazz Pharmaceuticals plc announced its financial results for the quarter ended March 31, 2026 by issuing a press release on May 5, 2026.
• The company furnished that press release to the SEC as Exhibit 99.1 in a Form 8-K reporting Results of Operations and Financial Condition (Item 2.02).

Key Details

• Filing date: May 5, 2026.
• Period covered: quarter ended March 31, 2026.
• Exhibit: Press Release dated May 5, 2026 filed as Exhibit 99.1 to the Form 8-K.
• Form 8-K was signed on behalf of Jazz by Philip L. Johnson, Executive Vice President and Chief Financial Officer.

Why It Matters

• This 8-K signals that Jazz has published its latest quarterly earnings and related figures; investors should review the press release (Exhibit 99.1) for revenue, earnings per share, operating results, and any guidance or management commentary.
• The Form 8-K itself furnishes the press release (rather than filing additional financial details in-line), so the press release is the primary source for the actual financial metrics and any near-term outlook that could affect the stock.
• Retail investors should check Jazz’s investor relations site or the attached Exhibit 99.1 to see the detailed quarterly results and listen for any scheduled earnings calls or investor presentations for additional context.